Looking for signs of growth in Biogen’s earnings
Biogen CEO Chris Viehbacher has been praised for reducing operating expenses. A return to revenue growth is still on the to-do list, however.
Biogen CEO Chris Viehbacher has been praised for reducing operating expenses. A return to revenue growth is still on the to-do list, however.
Wellness officers? Code Lavender teams? Mindfulness meditation? These aren’t the solutions to physician burnout and moral injury.
AUA 2024, N-803 plus BCG, Non Muscle Invasive Bladder Cancer (NMIBC), BCG Refractory, QUILT 3032 trial, ANKTIVA, interleukin-15 superagonist (IL-15), BCG-unresponsive high-grade NMIBC.
AUA 2024, non-muscle invasive bladder cancer (NMIBC), trans urethral resection of bladder tumor (TURBT), HG T1 bladder cancer, Replacing ReTUR with Cystoscopy, HuNIRe trial, urine cytology,…
AUA 2024 efficacy of repeat BCG challenge in patients with “BCG unresponsive” non-muscle invasive bladder cancer (NMIBC), BCG-unresponsive NMIBC,
Download STAT’s e-book to explore the challenges and steps to improve care for an aging population.
A new report suggests that the Texas man who wasinfected with bird flu virus may be the first detected case H5N1 transmitting from a mammal…
Andrea Apolo joins Sam Chang in discussing the AMBASSADOR study, focusing on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma. The study showed improved disease-free survival with…
On May 8, join us for a conversation with practicing neurologists about overcoming current hurdles involved in diagnosing, treating, and monitoring patients in a new…
AUA 2024 third interim analysis of the DARolutamide ObservationaL (DAROL) study, nonmetastatic castration-resistant prostate cancer (nmCRPC), DAROL study, darolutamide, phase 3 ARAMIS trial.
Amgen said it’s “very encouraged” by interim Phase 2 data for its obesity drug, quickly sparking investor interest. Here are the burning questions surrounding Amgen’s…